Kim MS - Search Results

1

US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.

Kim MS, Prasad V. Kim MS, et al. Cancer. 2020 Oct 1;126(19):4270-4272. doi: 10.1002/cncr.33058. Epub 2020 Jul 9. Cancer. 2020. PMID: 32644193 Free article.

2

Cancer screening: A modest proposal for prevention.

Kim MS, Nishikawa G, Prasad V. Kim MS, et al. Cleve Clin J Med. 2019 Mar;86(3):157-160. doi: 10.3949/ccjm.86a.18092. Cleve Clin J Med. 2019. PMID: 30849032 Free article. No abstract available.

3

Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals.

Kim MS, Prasad V. Kim MS, et al. JAMA Netw Open. 2019 May 3;2(5):e193981. doi: 10.1001/jamanetworkopen.2019.3981. JAMA Netw Open. 2019. PMID: 31099871 Free PMC article.

4

The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab.

Kim MS, Prasad V. Kim MS, et al. JAMA Intern Med. 2020 Feb 1;180(2):315-317. doi: 10.1001/jamainternmed.2019.4694. JAMA Intern Med. 2020. PMID: 31657842 Free PMC article. Review.

5

Persistent challenges with treating multiple myeloma early.

Goodman AM, Kim MS, Prasad V. Goodman AM, et al. Among authors: kim ms. Blood. 2021 Jan 28;137(4):456-458. doi: 10.1182/blood.2020009752. Blood. 2021. PMID: 33236046 Free article.

6

Approval and Coverage of Cancer Drugs in England, Canada, and the US.

Prasad V, Kim MS. Prasad V, et al. Among authors: kim ms. JAMA Intern Med. 2021 Apr 1;181(4):509-510. doi: 10.1001/jamainternmed.2020.8587. JAMA Intern Med. 2021. PMID: 33616600 Free article. No abstract available.

7

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020.

Haslam A, Kim MS, Prasad V. Haslam A, et al. Among authors: kim ms. Ann Oncol. 2021 Jul;32(7):926-932. doi: 10.1016/j.annonc.2021.04.003. Epub 2021 Apr 20. Ann Oncol. 2021. PMID: 33862157 Free article.

8

When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100.

Kim MS, Prasad V. Kim MS, et al. BMJ Evid Based Med. 2022 Jun;27(3):151-152. doi: 10.1136/bmjebm-2021-111702. Epub 2021 Jun 3. BMJ Evid Based Med. 2022. PMID: 34083211 Free article. No abstract available.

9

New drugs and options can enhance patient outcomes: But can they also erode them?

Kim MS, Prasad V. Kim MS, et al. Eur J Cancer. 2021 Sep;154:1-3. doi: 10.1016/j.ejca.2021.04.047. Epub 2021 Jun 30. Eur J Cancer. 2021. PMID: 34217009 Free article.

10

The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009-2018.

Haslam A, Gill J, Crain T, Herrera-Perez D, Chen EY, Hilal T, Kim MS, Prasad V. Haslam A, et al. Among authors: kim ms. BMC Cancer. 2021 Aug 3;21(1):889. doi: 10.1186/s12885-021-08632-8. BMC Cancer. 2021. PMID: 34344325 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,142 results

Search Page

Filters